Related Experiment Videos
Flow cytometric analysis does not reliably differentiate benign from malignant phaeochromocytoma
A P Heaney1, D O'Rourke, K Arthur
1Sir George E. Clark Metabolic Unit, Royal Victoria Hospital, Belfast, Northern Ireland, UK.
Clinical Endocrinology
|February 1, 1996
Summary
Flow cytometry for DNA content in phaeochromocytoma does not reliably predict malignancy. A diploid DNA pattern, often indicating benign disease, was observed in patients who later developed recurrent phaeochromocytoma.
Area of Science:
- Endocrinology
- Oncology
- Pathology
Background:
- Differentiating benign from malignant phaeochromocytoma is clinically challenging.
- Previous studies suggested DNA flow cytometry could predict malignancy, with diploid patterns indicating benign disease.
Purpose of the Study:
- To evaluate the utility of DNA flow cytometry in predicting malignant behavior of phaeochromocytoma.
- To determine if nuclear DNA content can reliably distinguish benign from malignant tumors.
Main Methods:
- DNA flow cytometry was performed on phaeochromocytoma tissue from 36 patients.
- Nuclear DNA content was analyzed to construct DNA histograms.
- Results were correlated with long-term clinical outcomes.
Main Results:
- Among 26 patients with over 5 years of follow-up, three died from malignant recurrence.
- A diploid DNA pattern was observed in two of these three patients with malignant recurrence.
- One patient with recurrent phaeochromocytoma 4 years post-surgery showed a diploid pattern.
Conclusions:
- DNA flow cytometry did not reliably differentiate benign from malignant phaeochromocytoma in this study.
- Three out of nine patients with a diploid pattern developed recurrent disease.
- Prolonged clinical and biochemical follow-up remains essential for managing phaeochromocytoma patients.